Welcome to Best Pharmacy at Havmeds! Go shopping!

Product ID: 428034

Reminder: The pictures displayed on this site maybe different from the actual appearance of the product,their maybe a delay in updating the recent picture if their a newly launched packaging from the manufacturer


PHOCAPMA is a particular small molecule MET inhibitor. Tabrecta (capmatinib) was approved by the US Food and Drug Administration in May 2020 for the treatment of patients with non-small cell lung cancer who have localised or metastatic MET exon 14 skippings (METEX 14) mutations (NSCLC). It's the fir

Trade name
Pharma 2 Vientiane
Main ingreadient
200mg*56 Tablets
Please negotiate the logistics method with customer service, customer service Whatsapp/Wechat
Please follow the doctor’s advice when taking medicines. The mall only guarantees the quality of the medicines and does not provide medical advice.

Authenticity guarantee

India Direct Mail

Privacy packaging

Pharmacy Direct


PHOCAPMA is a receptor tyrosine kinase that activates signaling pathways involved in organ regeneration and tissue repair. Due to aberrant c-Met activation, which can be caused by mutations, amplification, or overexpression, multiple downstream signaling pathways, including STAT3, PI3K/ATK, and RAS/MAPK, are overactivated. Non-small cell lung cancer (NSCLC) has been linked to mutations in the MET gene, with a rate of MET amplification ranging from 1.4 percent to 21% in EGFR-TKI-naive patients with NSCLC. Because of this, c-Met has become a desirable target in the therapy of NSCLC.
Related Products
Copyright 2023 havmeds.com. All Rights Reserved
Call Us